National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)

Human A1PI (Prolastin ®)  is indicated for long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).


Rapid Review

Commenced Completed Outcome
05/05/2017 08/06/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price


The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.